BofA: Investors pour into bonds, pull back from crypto
In a challenging market environment, Owens & Minor Inc. (OMI) stock has reached a 52-week low, touching down at $6.83. The healthcare solutions company has faced significant headwinds over the past year, reflected in a stark 1-year change with a decline of 67.55%. Investors have shown concern as the stock plummeted to this low point, marking a notable downturn from its previous performance. The company, which specializes in medical supplies and logistics, is navigating through a complex healthcare landscape that has impacted its stock valuation and investor confidence. With analyst targets ranging from $12 to $14 and earnings expected in 9 days, InvestingPro subscribers can access 10+ additional exclusive tips and comprehensive analysis to make informed investment decisions.
In other recent news, Owens & Minor, Inc. released preliminary financial results for the fourth quarter and full year ending December 31, 2024, which fell short of market expectations. The company reported a net loss of between $311 and $288 million for the fourth quarter, with adjusted EBITDA ranging from $135 to $140 million, missing the consensus estimate of $155.5 million. Revenue for the quarter is projected to be between $2.67 and $2.70 billion, below the expected $2.72 billion. Owens & Minor also anticipates a non-cash goodwill impairment charge of approximately $310 million in its Apria division. For the full year 2024, the company expects revenue between $10.67 and $10.70 billion, with a net loss ranging from $378 to $355 million. Analysts from Leerink Partners and Citi have expressed concerns about the company’s performance, particularly in relation to the upcoming acquisition of Rotech Healthcare Holdings, Inc. Leerink Partners maintains a market perform rating, while Citi holds a buy rating, attributing the lower results to the Patient Direct business. Owens & Minor’s CEO, Edward A. Pesicka, highlighted the growth of the Patient Direct segment and the reduction of total debt by over $240 million in 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.